Extended Effectiveness of the Etonogestrel-Releasing Contraceptive Implant and the 20 µg Levonorgestrel-Releasing Intrauterine System for 2 Years Beyond U.S. Food and Drug Administration Product Labeling

Moazzam Ali; Luis Bahamondes; Sihem Bent Landoulsi

doi:10.9745/GHSP-D-17-00296

Extended Effectiveness of the Etonogestrel-Releasing Contraceptive Implant and the 20 µg Levonorgestrel-Releasing Intrauterine System for 2 Years Beyond U.S. Food and Drug Administration Product Labeling

Glob Health Sci Pract. 2017 Dec 28;5(4):534-539. doi: 10.9745/GHSP-D-17-00296. Print 2017 Dec 28.

Authors

Moazzam Ali¹, Luis Bahamondes², Sihem Bent Landoulsi³

Affiliations

¹ Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland. alimoa@who.int.
² Family Planning Clinic, Department of Obstetrics and Gynaecology, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
³ Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.

Abstract

Recently published evidence from 2 large studies find that the duration of effectiveness of the etonorgestrel-releasing contraceptive implant to be at least 5 years (compared with the current 3-year label), and for the 20 µg levonorgestrel-releasing intrauterine system at least 7 years (compared with the current 5-year label).

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Contraceptive Agents, Female / administration & dosage
Contraceptive Agents, Female / pharmacology*
Desogestrel / administration & dosage
Desogestrel / pharmacology*
Drug Implants*
Female
Humans
Intrauterine Devices, Medicated*
Levonorgestrel / administration & dosage
Levonorgestrel / pharmacology*
Product Labeling
Randomized Controlled Trials as Topic
Time Factors
United States
United States Food and Drug Administration

Substances

Contraceptive Agents, Female
Drug Implants
etonogestrel
Levonorgestrel
Desogestrel

Grants and funding

001/WHO_/World Health Organization/International